Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11 GBX | 0.00% | -4.35% | +4.76% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.76% | 11.54M | |
+60.19% | 55.07B | |
-1.53% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+12.27% | 26.28B | |
-21.10% | 18.93B | |
+6.86% | 13.03B | |
+28.50% | 12.26B | |
+26.38% | 12.21B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment